LIMEDIKA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 159,753,915 | 178,798,402 | 194,101,545 | 213,779,982 | 240,640,368 | 268,461,894 | 301,401,164 | 348,323,711 |
| Profit before tax | 2,597,336 | 3,370,451 | 3,400,635 | 3,290,007 | 5,344,954 | 6,087,104 | 6,730,560 | 7,902,120 |
| Net profit | 2,115,039 | 2,589,665 | 2,835,373 | 2,624,594 | 4,407,845 | 5,017,558 | 5,977,274 | 6,523,590 |
| Equity | 5,066,902 | 3,856,134 | 4,049,308 | 3,714,679 | 5,468,143 | 5,973,304 | 6,933,020 | 7,479,336 |
| Liabilities | 43,702,593 | 46,427,379 | 52,924,247 | 55,338,507 | 67,182,892 | 71,118,644 | 71,661,065 | 78,319,241 |
| Non-current assets | 11,930,024 | 7,098,010 | 7,578,818 | 7,237,841 | 10,455,927 | 17,041,535 | 6,765,258 | 9,780,934 |
| Current assets | 37,228,338 | 43,770,891 | 50,002,474 | 52,595,040 | 62,688,317 | 60,543,491 | 72,669,291 | 77,322,493 |
| Total assets | 49,158,362 | 50,868,901 | 57,581,292 | 59,832,881 | 73,144,244 | 77,585,026 | 79,434,549 | 87,103,427 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 11,160,270 | 13,061,619 | 13,059,163 |
| Social insurance contributions | - | - | - | - | - | 2,140,853 | 2,384,728 | 2,669,074 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +1.6% | +11.9% | +8.6% | +10.1% | +12.6% | +11.6% | +12.3% | +15.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 4.3% | 5.1% | 4.9% | 4.4% | 6.0% | 6.5% | 7.5% | 7.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 41.7% | 67.2% | 70.0% | 70.7% | 80.6% | 84.0% | 86.2% | 87.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 1.3% | 1.4% | 1.5% | 1.2% | 1.8% | 1.9% | 2.0% | 1.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.6% | 1.9% | 1.8% | 1.5% | 2.2% | 2.3% | 2.2% | 2.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 8.6 | 12.0 | 13.1 | 14.9 | 12.3 | 11.9 | 10.3 | 10.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 657,198 | 675,561 | 632,253 | 632,641 | 676,748 | 789,400 | 880,217 | 989,790 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
LIMEDIKA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-08-28 | 2025-08-29 | 5061.16 |
| 2025-08-19 | 2025-08-21 | 5061.16 |
LIMEDIKA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
LIMEDIKA, UAB (code 134056779) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €348.32M, up 15.6% year on year and 29.8% over two years, showing a steady expansion in scale. Net profit reached €6.52M in 2025, compared with €5.98M in 2024 and €5.02M in 2023. Profitability remained stable, with a net margin of 1.9% in 2025 and 2.0% in 2024. The balance sheet also expanded: total assets increased to €87.10M in 2025 from €79.43M in 2024 and €77.59M in 2023, while equity rose to €7.48M. Liabilities increased to €78.32M. Key efficiency indicators remained solid, with asset turnover at 4.00x and return on assets at 7.5% in 2025. Return on equity was 87.2%, reflecting the company’s relatively modest equity base. Revenue per employee was €992.4K, while profit per employee was €18.6K, indicating high operating productivity in 2025.